Breakthrough, cost-effective solutions for diseases affecting heart valves
SAT is redefining the treatment of heart valve diseases. As a world-first, we are able to offer cost effective and durable transcatheter aortic valve solutions for Rheumatic Heart Disease (RHD) and Degenerative Heart Disease (DHD) patients, in both developed and emerging economies.
Beyond the established –
without skipping a beat
Addressing complexity
through simplicity
Truly flow-permissive